Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Patients with Leptomeningeal Metastasis Evaluated

Clin Breast Cancer; ePub 2016 Jul 25; Morikawa, et al

Publish date:: September 13, 2016

Surviving leptomeningeal metastasis remains poor for people with breast cancer even though some improvement has been seen of late, according to a retrospective review involving 318 individuals.

Participants were diagnosed with leptomeningeal metastasis between 1998 and 2013 at Memorial Sloan Kettering Cancer Center. Among the results:

• 44% were HR+ HER2^_, 18% were HR⁺HER2⁺, 9% were HR^_HER2⁺, and 26% were triple-negative.

• Median survival was 3.5 months; 1 in every 5 survived >1 year.

• Diagnosis after 2006, HER2⁺ subtype, higher performance status, cranial-only involvement, and no evidence of noncentral nervous system disease were linked with improved survival.

Citation: Morikawa A, Jordan L, Rozner R, et al. Characteristics and outcomes of patients with breast cancer with leptomeningeal metastasis. [Published online ahead of print July 25, 2016]. Clin Breast Cancer. doi:10.1016/j.clbc.2016.07.002.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Study: Doctors underreport side effects of breast irradiation,

No edge for anastrozole over tamoxifen in DCIS,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients,